Industry
Biotechnology
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Loading...
Open
15.77
Mkt cap
1.6B
Volume
291K
High
16.38
P/E Ratio
-16.86
52-wk high
18.07
Low
15.51
Div yield
N/A
52-wk low
10.90
Portfolio Pulse from
November 06, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:28 am
Portfolio Pulse from Avi Kapoor
October 31, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 8:38 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 8:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 9:43 am
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 5:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 8:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 4:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.